European Surveillance of Antimicrobial Consumption: outpatient systemic antiviral use in Europe
Abstract number: O478
Adriaenssens N., Coenen S., Muller A., Vankerckhoven V., Goossens H.
Objectives: To assess the total outpatient systemic antiviral use in Europe and to identify the antiviral substances most commonly used before the outbreak of the A/H1N1 pandemic as a historical reference.
Methods: The European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be) project, now funded by the European Centre for Disease Prevention and Control (ECDC; agreement number 2007/001), continues to collect data on antimicrobial consumption for all Member States, candidate countries and European Free Trade Association-European Economic Area countries using the anatomical therapeutic chemical (ATC) classification and the defined daily dose (DDD) measurement unit. For 2007, data on outpatient use of all antivirals for systemic use (ATC J05), aggregated at the level of the active substance, was collected and use was expressed in DDD (WHO ATC/DDD, version 2008) per 1000 inhabitants per day (DID).
Results: Total outpatient systemic antiviral use in 2007 in 11 European countries varied by a factor of 6.9 between the country with the highest (1.5 DID in the Netherlands) and the country with the lowest (0.2 DID in Finland) use. In most countries substances to treat HIV infection (ATC J05AE, J05AF0107, J05AF09, J05AG, J05AR, J05AX02, J05AX05 and J05AX0709) represented more than 50% of the total outpatient systemic antiviral use. In Finland, Denmark, Italy and Luxembourg nucleosides and nucleotides excluding reverse transcriptase inhibitors (ATC J05AB) represented more than 80% of the total outpatient antiviral use. The use of neuraminidase inhibitors (ATC J05AH) was the highest in Austria (0.02 DID) and varied from 3.42% in Denmark to no use reported in Belgium.
Conclusion: Our study demonstrates a variation of outpatient systemic antiviral use in Europe as striking as that of outpatient systemic antibiotic, antimycotic and antifungal use. More in-depth data on outpatient systemic viral use from more countries are needed to explain this variation. The ESAC data facilitate auditing of antiviral prescribing and evaluation of the implementation of guidelines and public health policies e.g. those related to A/H1N1.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|